Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSMI conditioning for high-risk hematologic malignancies
NCT02122081Phase 1Completed
- Start
- Jul 2015
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). Primary endpoints: Transplant-Related Mortality at Day 30 and Rate of Grade II/III Organ Toxicity at 30 days. Started Jul 2015; status: completed.
02
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02122081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122081.